First Case of FLT3-Tyrosine Kinase Domain Mutant Acute Myeloid Leukemia With Unusual Onset as Isolated Bilateral Testicular Myeloid Sarcoma

Basit Öğe Kaydı
dc.contributor.authorErol, Veysel
dc.contributor.authorCagliyan, Gulsum Akgun
dc.contributor.authorUfuk, Furkan
dc.contributor.authorDemir, Derya
dc.date.accessioned2024-08-31T07:48:23Z
dc.date.available2024-08-31T07:48:23Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractTesticular myeloid sarcoma (TMS) is a challenging pathology often posing diagnostic difficulties due to the poorly differentiated nature of tumor cells at the initial presentation. The delay in diagnosis significantly impacts patient life expectancy, emphasizing the need for prompt identification and treatment initiation. In certain cases, the presence of the Fms-like tyrosine kinase ( FLT3 ) mutation adds complexity to the disease, requiring tailored therapeutic approaches. In this report, we present a unique case of bilateral TMS with FLT3 tyrosine kinase domain ( TKD ) mutation. The patient exhibited an aggressive clinical course, initially misdiagnosed with orchitis during the initial evaluation. Subsequent reevaluation of the testicular biopsy at a second center led to an accurate diagnosis, highlighting the importance of thorough examination in challenging cases. Given the emerging significance of FLT3 mutations in myeloid sarcomas, comprehensive testing for all FLT3 variants is crucial to determine the appropriate treatment modality. This case underscores the need for increased awareness among healthcare professionals regarding the diagnostic nuances and potential genetic variations associated with TMS. Furthermore, the inclusion of tyrosine kinase inhibitors, such as midostaurin or gilteritinib, especially in the presence of FLT3 mutations, may significantly impact treatment outcomes. This report contributes to the growing body of literature on TMS and highlights the importance of considering FLT3 mutations in the diagnostic and therapeutic decision -making process for improved patient care.en_US
dc.identifier.doi10.7759/cureus.58140
dc.identifier.issn2168-8184
dc.identifier.issue4en_US
dc.identifier.pmid38738062en_US
dc.identifier.urihttps://doi.org/10.7759/cureus.58140
dc.identifier.urihttps://hdl.handle.net/11454/104767
dc.identifier.volume16en_US
dc.identifier.wosWOS:001222187700020en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofCureus Journal of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240831_Uen_US
dc.subjectFlt-3 Mutationen_US
dc.subjectMidostaurineen_US
dc.subjectSystemic Chemotherapyen_US
dc.subjectTesticular Myeloid Sarcomaen_US
dc.subjectAcute Myeloid Leukemiaen_US
dc.titleFirst Case of FLT3-Tyrosine Kinase Domain Mutant Acute Myeloid Leukemia With Unusual Onset as Isolated Bilateral Testicular Myeloid Sarcomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu